Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Glimepiride

A sulfonylurea for type 2 diabetes: it stimulates the pancreatic beta cells to release more insulin, so it only works if the pancreas still produces some. Patented in 1979, it was approved in 1995. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.

Did you know?The blood sugar lowering effect of sulfonylureas was discovered by chance in 1942 in Montpellier, when Marcel Janbon noticed sharp drops in blood sugar in patients treated with a sulfonamide for typhoid.

GlimepirideGo to the active ingredient →
GlimepirideActive ingredientGlimepirideCat. No. P-G041-001CAS 93479-97-1
Glimepiride-d4Isotopically labelledGlimepiride-d4Cat. No. P-G041-010CAS 1131981-29-7

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.